12 Best Medical Stocks To Buy Under $20

Page 2 of 11

10. Organon & Co. (NYSE:OGN)

Share Price as of January 8: $16.00

Number of Hedge Fund Holders: 32

Organon & Co. (NYSE:OGN) is a global healthcare and pharmaceutical company that is primarily focused on improving women’s health and well-being. The company’s portfolio and innovation pipeline is focused on various areas, including bacterial vaginosis, breast cancer, contraception, endometriosis, menopause, polycystic ovarian syndrome (PCOS), and postpartum hemorrhage (PPH). Organon & Co. (NYSE:OGN) provides a diverse range of over 60 medicines and products in women’s health, biosimilars, and a broad portfolio of established medications across various therapeutic areas.

The company has a strong lineup of products and is actively seeking to enhance its offerings. Organon & Co.’s (NYSE:OGN) largest product, Nexplanon, is expected to generate $1 billion in revenue in 2025. The recent acquisition of Dermavant Sciences Ltd. in October 2024 enhanced the company’s portfolio in immuno-dermatology with innovative treatments like VTAMA, allowing for further growth opportunities. On December 16, 2024, Organon & Co. (NYSE:OGN) announced FDA’s approval for VTAMA (tapinarof) cream for treating atopic dermatitis in adults and children aged two and older.

The company has also maintained disciplined operating costs while driving growth. Organon & Co. (NYSE:OGN) aims to achieve approximately $1 billion in free cash flow for 2024. As of November, the company had already generated nearly $700 million in free cash flow. This strong cash flow supports its dividend payments and provides the flexibility to invest in high-potential assets. The Board of Directors declared a quarterly dividend of $0.28 per share, reflecting the company’s commitment to returning value to shareholders while also focusing on future growth.

Page 2 of 11